BRPI0912668A2 - composto e composições como inibidores de quinase - Google Patents

composto e composições como inibidores de quinase

Info

Publication number: BRPI0912668A2
Authority: BR; Brazil
Prior art keywords: compositions; compound; kinase inhibitors; kinase; inhibitors
Prior art date: 2008-05-13

Application number

BRPI0912668A

Other languages

English (en)

Inventor

Gregory Chopiuk

Ha-Soon Choi

Pamela A Albaugh

Paul Vincent Rucker

Yi Fan

Zhicheng Wang

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-13

Filing date

2009-05-07

Publication date

2016-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41202804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912668(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-07 Application filed by Irm Llc filed Critical Irm Llc

2016-01-26 Publication of BRPI0912668A2 publication Critical patent/BRPI0912668A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Virology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)

BRPI0912668A 2008-05-13 2009-05-07 composto e composições como inibidores de quinase BRPI0912668A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5287908P	2008-05-13	2008-05-13
US15287209P	2009-02-16	2009-02-16
PCT/US2009/043073 WO2009140128A2 (en)	2008-05-13	2009-05-07	Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0912668A2 true BRPI0912668A2 (pt)	2016-01-26

Family

ID=41202804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0912668A BRPI0912668A2 (pt)	2008-05-13	2009-05-07	composto e composições como inibidores de quinase

Country Status (27)

Country	Link
US (1)	US8507488B2 (pt)
EP (1)	EP2300469B1 (pt)
JP (2)	JP5492194B2 (pt)
KR (1)	KR101324804B1 (pt)
CN (1)	CN102056927B (pt)
AR (1)	AR071778A1 (pt)
AU (1)	AU2009246687B2 (pt)
BR (1)	BRPI0912668A2 (pt)
CA (1)	CA2722418C (pt)
CL (1)	CL2009001160A1 (pt)
CO (1)	CO6321286A2 (pt)
CR (1)	CR11797A (pt)
DO (1)	DOP2010000349A (pt)
EA (1)	EA019507B1 (pt)
EC (1)	ECSP10010676A (pt)
ES (1)	ES2548135T3 (pt)
IL (1)	IL208993A0 (pt)
MA (1)	MA32393B1 (pt)
MX (1)	MX2010012457A (pt)
NI (1)	NI201000194A (pt)
PA (1)	PA8826501A1 (pt)
PE (1)	PE20091849A1 (pt)
SV (1)	SV2010003733A (pt)
TW (1)	TW201012820A (pt)
UY (1)	UY31821A (pt)
WO (1)	WO2009140128A2 (pt)
ZA (1)	ZA201008476B (pt)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7868001B2 (en)	2007-11-02	2011-01-11	Hutchison Medipharma Enterprises Limited	Cytokine inhibitors
CN102224153B (zh)	2008-09-22	2014-04-30	阵列生物制药公司	作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物
LT3106463T (lt)	2008-10-22	2018-06-25	Array Biopharma, Inc.	Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai
JP5709276B2 (ja)	2009-04-20	2015-04-30	オースペックスファーマシューティカルズ，エルエルシー	ヤヌスキナーゼ３のピペリジンインヒビター
US20110053968A1 (en)	2009-06-09	2011-03-03	Auspex Pharmaceuticals, Inc.	Aminopyrimidine inhibitors of tyrosine kinase
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8415381B2 (en)	2009-07-30	2013-04-09	Novartis Ag	Heteroaryl compounds and their uses
US20130065883A1 (en) *	2010-02-18	2013-03-14	Centro Nacional de Investigaceiones Oncologicas (CNIO)	Triazolo [4, 5- B] Pyridin Derivatives
US20130005733A1 (en)	2010-03-09	2013-01-03	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
GB201004200D0 (en) *	2010-03-15	2010-04-28	Univ Basel	Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
CA2791020A1 (en) *	2010-04-28	2011-11-03	Daiichi Sankyo Company, Limited	[5,6] heterocyclic compound
EP2571878B1 (en) *	2010-05-17	2018-10-17	Incozen Therapeutics Pvt. Ltd.	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
PT3205654T (pt)	2010-05-20	2019-04-22	Array Biopharma Inc	Compostos macrocíclicos como inibidores de cinases trk
WO2012016133A2 (en) *	2010-07-29	2012-02-02	President And Fellows Of Harvard College	Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) *	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
EP2630134B9 (en) *	2010-10-20	2018-04-18	Pfizer Inc	Pyridine-2- derivatives as smoothened receptor modulators
EP2463289A1 (en) *	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2012097478A1 (en) *	2011-01-21	2012-07-26	Abbott Laboratories	Bicyclic carboxamide inhibitors of kinases
ES2551592T3 (es) *	2011-02-25	2015-11-20	Novartis Ag	Pirazolo[1,5-a]piridinas como inhibidores de TRK
US8673905B2 (en) *	2011-03-17	2014-03-18	Hoffmann-La Roche Inc.	Imidazo pyrazines
WO2012125667A1 (en) *	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
BR112013029201B1 (pt)	2011-05-13	2022-08-09	Array Biopharma Inc	Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas
AU2012280508A1 (en) *	2011-07-01	2013-12-12	Bayer Intellectual Property Gmbh	Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
UY34305A (es)	2011-09-01	2013-04-30	Novartis Ag	Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9090630B2 (en) *	2011-09-30	2015-07-28	Oncodesign S.A.	Macrocyclic FLT3 kinase inhibitors
CN104114553B (zh)	2011-12-12	2017-03-01	雷迪博士实验室有限公司	作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5‑a]吡啶
PT2834243T (pt) *	2012-03-09	2018-08-01	Lexicon Pharmaceuticals Inc	Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização
EP3235499A3 (en) *	2012-03-09	2018-01-17	Lexicon Pharmaceuticals, Inc.	Inhibition of adaptor associated kinase 1 for the treatment of pain
TWI585088B (zh) *	2012-06-04	2017-06-01	第一三共股份有限公司	作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
KR102171706B1 (ko) *	2012-07-09	2020-10-30	얀센 파마슈티카 엔.브이.	포스포디에스테라아제 10 효소의 억제제
WO2014022569A1 (en) *	2012-08-03	2014-02-06	Principia Biopharma Inc.	Treatment of dry eye
LT3181567T (lt)	2012-09-10	2019-07-25	Principia Biopharma Inc.	Pirazolpirimidino junginiai kaip kinazės slopikliai
CN104640863B (zh) *	2012-09-20	2016-06-08	山东亨利医药科技有限责任公司	嘧啶胺衍生物及其制备方法和应用
CN104854101B (zh)	2012-11-06	2018-05-01	上海复尚慧创医药研究有限公司	Alk激酶抑制剂
US9790178B2 (en)	2012-11-13	2017-10-17	Array Biopharma Inc.	Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en)	2012-11-13	2017-10-17	Array Biopharma Inc.	N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CA2891334C (en)	2012-11-13	2021-10-19	Array Biopharma Inc.	Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
RU2677667C2 (ru) *	2012-11-13	2019-01-18	Эррэй Биофарма Инк.	Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka
WO2014078417A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en)	2012-11-13	2014-05-22	Array Biopharma Inc.	N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
PT2925757T (pt)	2012-11-19	2018-01-09	Novartis Ag	Compostos e composições para o tratamento de doenças parasitárias
US9757395B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
ES2831625T3 (es) *	2013-02-20	2021-06-09	Kala Pharmaceuticals Inc	Compuestos terapéuticos y sus usos
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
CN105431148A (zh)	2013-03-07	2016-03-23	加利菲亚生物公司	混合谱系激酶抑制剂及治疗方法
JP6378308B2 (ja) *	2013-03-13	2018-08-22	ボストンバイオメディカル，インコーポレイテッド	がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
AU2014230125A1 (en) *	2013-03-15	2015-10-29	Oncodesign S.A.	Macrocyclic salt-inducible kinase inhibitors
JP2016518388A (ja)	2013-04-30	2016-06-23	オティトピックインク．	乾燥粉末配合および使用方法
WO2015017528A1 (en) *	2013-07-30	2015-02-05	Blueprint Medicines Corporation	Pik3c2g fusions
US10407509B2 (en)	2013-07-30	2019-09-10	Blueprint Medicines Corporation	NTRK2 fusions
AR097543A1 (es) *	2013-09-06	2016-03-23	Lexicon Pharmaceuticals Inc	COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) *	2013-09-06	2015-11-16	Lexicon Pharmaceuticals Inc	吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
KR20220027271A (ko)	2014-02-21	2022-03-07	프린시피아 바이오파마, 인코퍼레이티드	Btk 억제제의 염 및 고체 형태
AU2015238296B2 (en) *	2014-03-27	2018-10-18	Janssen Pharmaceutica Nv	Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors
CN106132967B (zh)	2014-03-27	2019-05-28	詹森药业有限公司	作为ros1抑制剂的化合物
CN103864800A (zh) *	2014-04-03	2014-06-18	定陶县友帮化工有限公司	6-氯咪唑并[1,2-b]哒嗪的合成方法
RU2719489C2 (ru)	2014-05-15	2020-04-17	Эррэй Биофарма Инк.	1-((3S,4R)-4-(3-ФТОРФЕНИЛ)-1-(2-МЕТОКСИЭТИЛ)ПИРРОЛИДИН-3-ИЛ)-3-(4-МЕТИЛ-3-(2-МЕТИЛПИРИМИДИН-5-ИЛ)-1-ФЕНИЛ-1Н-ПИРАЗОЛ-5-ИЛ)МОЧЕВИНА В КАЧЕСТВЕ ИНГИБИТОРА TrkA КИНАЗЫ
WO2015183836A1 (en) *	2014-05-27	2015-12-03	Brian Haynes	Compositions, methods, and uses related to ntrk2-tert fusions
WO2015183837A1 (en) *	2014-05-27	2015-12-03	Brian Haynes	Compositions, methods, and uses related to ntrk2-tert fusions
ES2687606T3 (es) *	2014-05-30	2018-10-26	Qilu Pharmaceutical Co., Ltd.	Derivado de bucle de dihidropirimido como inhibidor de HBV
RU2695220C2 (ru)	2014-06-30	2019-07-22	Тарведа Терапьютикс, Инк.	Нацеленные конъюгаты и частицы и их составы
EP3215175A4 (en) *	2014-11-06	2018-06-27	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
AU2015346046B2 (en)	2014-11-16	2020-06-25	Array Biopharma, Inc.	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
HUE067779T2 (hu)	2014-12-15	2024-11-28	Cmg Pharmaceutical Co Ltd	Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként
ES2843323T3 (es)	2014-12-18	2021-07-16	Principia Biopharma Inc	Tratamiento de pénfigo
US20180305350A1 (en)	2015-06-24	2018-10-25	Principia Biopharma Inc.	Tyrosine kinase inhibitors
CA2988601C (en) *	2015-07-02	2021-12-07	F. Hoffmann-La Roche Ag	Bicyclic lactams and methods of use thereof
TN2019000271A1 (en)	2015-10-26	2021-01-07	Univ Colorado Regents	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US11160871B2 (en)	2015-10-28	2021-11-02	Tarveda Therapeutics, Inc.	SSTR-targeted conjugates and particles and formulations thereof
TN2018000335A1 (en)	2016-04-04	2020-01-16	Loxo Oncology Inc	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
SI3800189T1 (sl)	2016-05-18	2023-11-30	Loxo Oncology, Inc.	Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN109600989B (zh)	2016-06-29	2022-11-04	普林斯匹亚生物制药公司	2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
EP3526219B1 (en)	2016-10-17	2021-12-15	F. Hoffmann-La Roche AG	Bicyclic pyridone lactams and methods of use thereof
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AU2017348826B2 (en) *	2016-10-28	2021-12-02	Centaurus Biopharma Co., Ltd.	Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
US11072607B2 (en)	2016-12-16	2021-07-27	Genentech, Inc.	Inhibitors of RIP1 kinase and methods of use thereof
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10786456B2 (en)	2017-09-22	2020-09-29	Otitopic Inc.	Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en)	2017-09-22	2023-11-30	Aspeya US Inc.	Dry powder compositions with magnesium stearate
CN111315384A (zh)	2017-11-23	2020-06-19	皮奎尔治疗公司	皮肤病的治疗
ES2908773T3 (es) *	2017-12-15	2022-05-03	Pyramid Biosciences Inc	Derivados de 5-(2-(2,5-difluorofenil)pirrolidin-1-il)-3-(1H-pirazol-1-il)pirazolo[1,5-a]pirimidina y compuestos relacionados como inhibidores de Trk quinasa para el tratamiento del cáncer
WO2019142128A1 (en) *	2018-01-18	2019-07-25	Integral Biosciences Private Limited	Dual inhibitors of alk5 and p38α map kinase
CN108218754B (zh) *	2018-01-23	2021-05-07	广东赛烽医药科技有限公司	一种2-(2,5-二氟苯基)吡咯烷的制备方法
SG11202006701TA (en) *	2018-01-29	2020-08-28	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof
WO2019169249A1 (en) *	2018-03-01	2019-09-06	The Johns Hopkins University	INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
US11459332B2 (en) *	2018-03-14	2022-10-04	Fochon Biosciences, Ltd.	Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors
WO2019204537A1 (en)	2018-04-20	2019-10-24	Genentech, Inc.	N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
GB201811825D0 (en) *	2018-07-19	2018-09-05	Benevolentai Bio Ltd	Organic compounds
JP7106162B2 (ja) *	2018-08-01	2022-07-26	シャンシー・ミコ・テクノロジー・カンパニー・リミテッド	神経系疾患を治療するための化合物及びその応用
US11969472B2 (en)	2018-08-22	2024-04-30	Cullgen (Shanghai), Inc.	Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP3841098A4 (en)	2018-08-22	2022-05-04	Cullgen (Shanghai), Inc.	TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE
CN111039946A (zh) *	2018-10-15	2020-04-21	上海轶诺药业有限公司	一类咪唑并芳环类化合物的制备和应用
CN111302995A (zh) *	2018-12-12	2020-06-19	上海复星星泰医药科技有限公司	一种2-(2,5-二氟苯基)-吡咯烷消旋体的制备方法
CN109942582B (zh) *	2019-03-15	2020-12-01	上海健康医学院	一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用
WO2020227484A1 (en) *	2019-05-09	2020-11-12	Bristol-Myers Squibb Company	Substituted benzimidazolone compounds
CN112142731B (zh) *	2019-06-28	2022-07-22	成都赜灵生物医药科技有限公司	一种2，4-二取代嘧啶衍生物及其制备方法和用途
CN116789681B (zh) *	2019-08-09	2025-09-12	四川科伦博泰生物医药股份有限公司	含有并环基团的咪唑并嘧啶类化合物、其制备方法及用途
WO2021038419A1 (en) *	2019-08-23	2021-03-04	Insilico Medicine Ip Limited	Kinase inhibitors and methods of synthesis and treatment
US12293809B2 (en)	2019-08-23	2025-05-06	Insilico Medicine Ip Limited	Workflow for generating compounds with biological activity against a specific biological target
WO2021047584A1 (en) *	2019-09-11	2021-03-18	Fochon Pharmaceuticals, Ltd.	SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
WO2021067749A2 (en) *	2019-10-02	2021-04-08	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for the treatment of osteoarthritis
KR20220080179A (ko)	2019-10-14	2022-06-14	프린시피아 바이오파마, 인코퍼레이티드	(R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
MX2022008930A (es) *	2020-01-22	2022-10-18	Benevolentai Bio Ltd	Composiciones farmaceuticas y sus usos.
KR20220130184A (ko)	2020-01-22	2022-09-26	프린시피아 바이오파마, 인코퍼레이티드	2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
WO2023205701A1 (en)	2022-04-20	2023-10-26	Kumquat Biosciences Inc.	Macrocyclic heterocycles and uses thereof
CN115697989B (zh)	2020-02-26	2025-03-18	上海睿跃生物科技有限公司	原肌球蛋白受体激酶(trk)降解化合物和使用方法
CN111393347B (zh) *	2020-04-30	2020-11-17	安徽德信佳生物医药有限公司	一种拉洛替尼中间体的合成方法
CN114315900B (zh) *	2020-09-30	2023-09-05	美迪西普胜医药科技(上海)有限公司	3-芳基吡唑并嘧啶类衍生物及其应用
AU2021403015A1 (en) *	2020-12-15	2023-08-03	Children's Hospital Medical Center	Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
AU2021440841A1 (en) *	2021-04-13	2023-10-19	Shenzhen Newdel Biotech Co., Ltd.	Alkynylphenylbenzamide compound and use thereof
JP7724011B2 (ja) *	2021-06-21	2025-08-15	メディノファーマスーティカルテクノロジー（チューハイ）カンパニーリミテッド	Ｔｒｋキナーゼ阻害剤化合物及びその使用
CA3223035A1 (en) *	2021-07-01	2023-01-05	Anheart Therapeutics (Hangzhou) Co., Ltd.	Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
CN113480543B (zh) *	2021-07-07	2022-05-17	无锡市第二人民医院	2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
CN113564121A (zh) *	2021-08-10	2021-10-29	合肥滴碧云生物科技有限公司	一种造血干细胞冻存方法
EP4540248A2 (en) *	2022-06-15	2025-04-23	Children's Hospital Medical Center	Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN117659020A (zh) *	2022-09-07	2024-03-08	苏州朗睿生物医药有限公司	一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2024054512A1 (en) *	2022-09-08	2024-03-14	Alterome Therapeutics, Inc.	Akt1 modulators
US20240124450A1 (en) *	2022-09-21	2024-04-18	Pfizer Inc.	Novel SIK Inhibitors
WO2024112721A1 (en) *	2022-11-21	2024-05-30	Cz Biohub Sf, Llc	ALLOSTERIC MODULATORS OF THE μ-OPIOID RECEPTOR AND CANNABINOID RECEPTOR 1
WO2024227051A1 (en) *	2023-04-28	2024-10-31	Kurome Therapeutics, Inc.	Irak inhibitor free base, salts, and polymorphic forms thereof
AU2024276994A1 (en)	2023-05-24	2025-10-23	Kumquat Biosciences Inc.	Heterocyclic compounds and uses thereof
TW202502779A (zh)	2023-06-30	2025-01-16	美商金橘生物科技公司	取代的雜芳族胺及其用途
CN117050031A (zh) *	2023-07-26	2023-11-14	扬州大学	氟代噻唑烷酮及其合成方法
WO2025029929A1 (en) *	2023-07-31	2025-02-06	Children's Hospital Medical Center	Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof
WO2025038525A1 (en) *	2023-08-11	2025-02-20	Bioventures, Llc	Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions
WO2025096855A1 (en)	2023-11-02	2025-05-08	Kumquat Biosciences Inc.	Degraders and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6316444B1 (en) *	1999-06-30	2001-11-13	Merck & Co., Inc.	SRC kinase inhibitor compounds
WO2001000213A1 (en) *	1999-06-30	2001-01-04	Merck & Co., Inc.	Src kinase inhibitor compounds
ES2254238T3 (es) *	1999-10-27	2006-06-16	Novartis Ag	Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
US7306631B2 (en)	2004-03-30	2007-12-11	The Procter & Gamble Company	Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
CA2586259A1 (en) *	2004-11-08	2006-05-11	Banyu Pharmaceutical Co., Ltd.	Novel fused imidazole derivative
JP2009502734A (ja) *	2005-07-29	2009-01-29	アステラス製薬株式会社	Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7750000B2 (en) *	2005-09-02	2010-07-06	Bayer Schering Pharma Ag	Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US20070078136A1 (en) *	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) *	2005-09-22	2010-05-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (en) *	2006-08-04	2010-12-22	Takeda Pharmaceutical	CONDENSED HETEROCYCLIC COMPOUND
AU2007292924A1 (en) *	2006-09-07	2008-03-13	Biogen Idec Ma Inc.	IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
DE602007013441D1 (de) *	2006-09-29	2011-05-05	Novartis Ag	Pyrazolopyrimidine als pi3k-lipidkinasehemmer
BRPI0718266A2 (pt) *	2006-10-30	2014-01-07	Novartis Ag	Compostos heterocíclicos como agentes anti-inflamatórios.
AR064420A1 (es)	2006-12-21	2009-04-01	Alcon Mfg Ltd	Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
AR067326A1 (es)	2007-05-11	2009-10-07	Novartis Ag	Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
FR2918061B1 (fr)	2007-06-28	2010-10-22	Sanofi Aventis	Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
CN102224153B (zh)	2008-09-22	2014-04-30	阵列生物制药公司	作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物

2009
- 2009-05-07 ES ES09747213.8T patent/ES2548135T3/es active Active
- 2009-05-07 MX MX2010012457A patent/MX2010012457A/es active IP Right Grant
- 2009-05-07 CA CA2722418A patent/CA2722418C/en not_active Expired - Fee Related
- 2009-05-07 KR KR1020107027784A patent/KR101324804B1/ko not_active Expired - Fee Related
- 2009-05-07 CN CN200980121828.XA patent/CN102056927B/zh not_active Expired - Fee Related
- 2009-05-07 BR BRPI0912668A patent/BRPI0912668A2/pt not_active IP Right Cessation
- 2009-05-07 EA EA201001774A patent/EA019507B1/ru not_active IP Right Cessation
- 2009-05-07 US US12/992,027 patent/US8507488B2/en active Active
- 2009-05-07 JP JP2011509564A patent/JP5492194B2/ja not_active Expired - Fee Related
- 2009-05-07 WO PCT/US2009/043073 patent/WO2009140128A2/en not_active Ceased
- 2009-05-07 EP EP09747213.8A patent/EP2300469B1/en active Active
- 2009-05-07 AU AU2009246687A patent/AU2009246687B2/en not_active Ceased
- 2009-05-12 UY UY0001031821A patent/UY31821A/es not_active Application Discontinuation
- 2009-05-13 AR ARP090101724A patent/AR071778A1/es unknown
- 2009-05-13 PA PA20098826501A patent/PA8826501A1/es unknown
- 2009-05-13 CL CL2009001160A patent/CL2009001160A1/es unknown
- 2009-05-13 TW TW098115907A patent/TW201012820A/zh unknown
- 2009-05-13 PE PE2009000671A patent/PE20091849A1/es not_active Application Discontinuation
2010
- 2010-10-28 IL IL208993A patent/IL208993A0/en unknown
- 2010-11-12 DO DO2010000349A patent/DOP2010000349A/es unknown
- 2010-11-12 SV SV2010003733A patent/SV2010003733A/es not_active Application Discontinuation
- 2010-11-12 NI NI201000194A patent/NI201000194A/es unknown
- 2010-11-18 CR CR11797A patent/CR11797A/es not_active Application Discontinuation
- 2010-11-25 ZA ZA2010/08476A patent/ZA201008476B/en unknown
- 2010-12-06 CO CO10153711A patent/CO6321286A2/es not_active Application Discontinuation
- 2010-12-10 MA MA33422A patent/MA32393B1/fr unknown
- 2010-12-13 EC EC2010010676A patent/ECSP10010676A/es unknown
2014
- 2014-01-29 JP JP2014014101A patent/JP2014098010A/ja active Pending

Also Published As

Publication number	Publication date
DOP2010000349A (es)	2010-11-30
CN102056927A (zh)	2011-05-11
ZA201008476B (en)	2012-02-29
PE20091849A1 (es)	2009-12-21
US8507488B2 (en)	2013-08-13
NI201000194A (es)	2011-03-15
EA019507B1 (ru)	2014-04-30
MA32393B1 (fr)	2011-06-01
CL2009001160A1 (es)	2010-06-11
WO2009140128A3 (en)	2010-01-07
TW201012820A (en)	2010-04-01
WO2009140128A2 (en)	2009-11-19
EA201001774A1 (ru)	2011-06-30
US20110166133A1 (en)	2011-07-07
AU2009246687B2 (en)	2012-08-09
CA2722418A1 (en)	2009-11-19
ES2548135T3 (es)	2015-10-14
JP2011520887A (ja)	2011-07-21
JP5492194B2 (ja)	2014-05-14
KR101324804B1 (ko)	2013-11-01
CA2722418C (en)	2013-09-17
ECSP10010676A (es)	2011-01-31
IL208993A0 (en)	2011-01-31
EP2300469A2 (en)	2011-03-30
EP2300469B1 (en)	2015-06-24
UY31821A (es)	2010-01-05
CN102056927B (zh)	2014-06-25
JP2014098010A (ja)	2014-05-29
PA8826501A1 (es)	2010-04-21
KR20110016931A (ko)	2011-02-18
AR071778A1 (es)	2010-07-14
CO6321286A2 (es)	2011-09-20
SV2010003733A (es)	2011-07-05
MX2010012457A (es)	2010-12-07
CR11797A (es)	2011-02-16
AU2009246687A1 (en)	2009-11-19

Publication	Publication Date	Title
BRPI0912668A2 (pt)	2016-01-26	composto e composições como inibidores de quinase
BRPI0914652A2 (pt)	2017-06-06	compostos e composições como inibidores de quinase
CY2020023I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
BRPI0906973A2 (pt)	2015-07-14	Compostos e composições como inibidores de cinase.
BRPI0911228A2 (pt)	2017-05-30	compostos e composições como inibidores de proteínas quinase
CY2019027I1 (el)	2019-11-27	Παραγωγα φωσφορου ως αναστολεις κινασης
BRPI0908849A2 (pt)	2015-08-25	Composto e composições como c-kit e inibidores de pdgfr quinase
BRPI0910979A2 (pt)	2016-01-05	compostos e composições como inibidores de quinase
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0914545A2 (pt)	2017-05-23	compostos e composições como inibidores de quinase
BRPI0811516A2 (pt)	2014-11-18	Compostos e composições como inibidores de c-kit e pdgfr cinase
SMT201400133B (it)	2014-11-10	Composti e composizioni come inibitori di protein chinasi
DK2634232T3 (da)	2022-06-07	Sammensætninger
BR112012004448A2 (pt)	2017-05-30	"compostos e composições como inibidores de proteína cinase"
BRPI0719797A2 (pt)	2017-10-24	compostos e composições como inibidores de proteína cinase
BRPI0906749A2 (pt)	2015-07-07	Composição
BRPI0913808A2 (pt)	2017-06-20	composição
BRPI0811065A2 (pt)	2014-12-02	Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0919708A2 (pt)	2015-12-08	composições antimicrobianas
EP2381760A4 (en)	2013-01-16	CORN PROTEIN COMPOSITION
BRPI0912475A8 (pt)	2018-03-20	compostos como inibidores de quinase
BRPI0917231A2 (pt)	2015-11-10	composição
DK2373293T3 (da)	2013-10-07	Sammensætninger med reduceret dimerdannelse
IT1392101B1 (it)	2012-02-09	Composizione comprendente isoflavoni

Legal Events

Date	Code	Title	Description
2016-06-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-09-27	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.